The aforementioned variables, including MRM, larger tumor size, lymph node involvement, ER and PgR positivity, and hormone therapy (except for tamoxifen), acted as independent prognostic factors for DFS events in the 5-year follow-up. This evidence concerns the gene PGR and neoplasm.